Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst

2025-12-16 16:10:08 ET

Thesis

Alector Inc. ( ALEC ) stock has had quite a volatile year. We saw great momentum from the company as it progressed with Latozinemab through the pipeline. However, in late October, we saw a less-than-positive data readout, which dropped shares by over 50%. Now heading into 2026, the stock has been re-rated somewhat and is now reading in the $1.50 range. While it is still very early days for the treatment, I see Nivisnebart as being the next big catalyst for the stock. The downside, though, is that, mechanistically speaking, it is very similar to Latozinemab, which I see as being a big swayer of investor confidence. That is why I think investors should hold until we see positive signs from the upcoming Nivisnebart Phase 2 PROGRESS-AD interim analysis data in early 2026. Year to date, the stock is down about 21% and appears to have a long road to recovery on the back of Nivisnebart....

Read the full article on Seeking Alpha

For further details see: